French industry bemoans loss of presence on regulatory bodies
This article was originally published in Scrip
Executive Summary
France's drug regulatory agency, Afssaps, has published details of the new membership of its various bodies and committees, including those responsible for drug approvals and pharmacovigilance. The move is noteworthy because the pharmaceutical industry no longer has representation on any of these committees - or indeed on the agency's board.